Pink SheetScripMedtech InsightHBW InsightGenerics BulletinIn Vivo

Generics Bulletin

Medtech Insight

Biosimilar Suffixes Appear Superfluous In Adverse Event Reporting

Oct 10 2018

• By Derrick Gingery

the word suffix on cubes

Related Content

Novel Biologics Will Get Suffixes (Or At Least One Did)

Nov 16 2017

Biosimilars: US FDA Education Campaign Is Non-Committal On Non-Medical Switching

Oct 25 2017

New CDER No. 2 May Impact FDA's Safety Monitoring Aspirations

Apr 18 2018

VA Changes Infliximab Biosimilars; Merck Formulary Win Could Drive Questions On Patient Switching

Oct 10 2018

Biosimilar Education Needed To Eliminate 'Nocebo' Effect, Pfizer Says

Aug 28 2018

FDA’s Burden Estimate On Biologic Naming Ignores Downstream Costs, Critics Say

Feb 16 2017

Sentinel For Biosimilars? Biologics Post-Market Monitoring Is Focus Of New Consortium

Feb 29 2016

Biosimilar Suffix Detractors Hope Private Studies Build Their Case

Oct 12 2016

FDA Biosimilar Education Campaign Will Need To Be Targeted

Sep 17 2015

Related Companies

Novartis AG

Amgen, Inc.

Teva Pharmaceutical Industries Ltd.

Johnson & Johnson

Celltrion, Inc.

Samsung Bioepis Co., Ltd.

Merck & Co., Inc.

Additional Topics

United States Biosimilars Drug Safety FDA Regulation Biologics BioPharmaceutical

More from Biosimilars

More from Products

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window